Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Poland / NCT00002462
Active, not recruiting Phase 3

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

NCT00002462 · tracked via the Priya Life Science Poland tracker
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 3
Started
1989-09
Last updated
2025-08-05

Condition(s) studied

Lymphoma

Investigational drug(s) / intervention(s)

bleomycin sulfate →doxorubicin hydrochloride →mechlorethamine hydrochlorideprednisone →procarbazine hydrochloridevinblastine sulfate →vincristine sulfate →low-LET cobalt-60 gamma ray therapylow-LET photon therapyradiation therapy

Study summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.

Eligibility

Sex
ALL
Min age
15 Years
Max age
70 Years
Healthy volunteers
No
DISEASE CHARACTERISTICS: Histologically proven clinical or pathological Stage III/IV Hodgkin's disease Pathological Stage IIIAS disease with the spleen as the only site of subdiaphragmatic involvement excluded PATIENT CHARACTERISTICS: Age: 15 to 70 Performance status: Not specified Life expectancy: No severe limits on life expectancy due to nonmalignant disease Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No severe cardiac disease that would preclude protocol therapy Pulmonary: No severe pulmonary disease that would preclude protocol therapy Other: No severe metabolic or neurologic disease that would preclude protocol therapy No concomitant or previous second malignancy except: Nonmelanomatous skin cancer In situ carcinoma of the cervix PRIOR CONCURRENT THERAPY: No prior therapy

Primary outcome measure(s)

Trial sites (56)

FacilityCityRegionStatus
Algemeen Ziekenhuis Middelheim Antwerp Belgium
A.Z. St. Jan Bruges Belgium
Hopital Universitaire Erasme Brussels Belgium
C.H.U. Saint-Pierre Brussels (Bruxelles) Belgium
Institut Jules Bordet Brussels (Bruxelles) Belgium
Centre Hospitalier Universitaire Brugmann Brussels (Bruxelles) Belgium
Centre Hospitalier Universitaire de Tivoli La Louvière Belgium
U.Z. Gasthuisberg Leuven Belgium
U.Z. Sint-Rafael Leuven Belgium
National Cancer Institute of Egypt Cairo Egypt
Institut Bergonie Bordeaux France
Centre Regional Francois Baclesse Caen France
Centre Hospitalier General Compiègne France
Centre Georges-Francois Leclerc Dijon France
Centre Leon Berard Lyon France
Hopital Edouard Herriot Lyon France
Centre Antoine Lacassagne Nice France
Hotel Dieu de Paris Paris France
Hopital Saint Antoine Paris France
Hopital Cochin Paris France
Hopital Necker Paris France
Hopital Jules Courmont - Centre Hospitalier Lyon Sud Pierre-Bénite France
Hopital Sud Rennes France
Centre Henri Becquerel Rouen France
Centre Medico-Chirurgical Foch Suresnes France
Centre Alexis Vautrin Vandœuvre-lès-Nancy France
Institut Gustave Roussy Villejuif France
Zentralkrankenhaus Bremen Germany
Centro di Riferimento Oncologico - Aviano Aviano Italy
Dipartimente di Oncologia di Torino Turin (Torino) Italy
Leyenburg Ziekenhuis 's-Gravenhage (Den Haag, the Hague) Netherlands
Groot Ziekengasthuis 's-Hertogenbosch 's-Hertogenbosch Netherlands
Medisch Centrum Alkmaar Alkmaar Netherlands
Antoni van Leeuwenhoekhuis Amsterdam Netherlands
Integraal Kankercentrum Amsterdam Amsterdam Netherlands
Slotervaart Ziekenhuis Amsterdam Netherlands
Onze Lieve Vrouwe Gasthuis Amsterdam Netherlands
Streekziekenhuizen Gooi-Noord Blaricum Netherlands
Catharina Ziekenhuis Eindhoven Netherlands
Medisch Spectrum Twente Enschede Netherlands

+ 16 more sites — see the full list on the official registry below.

On this site

📄 Deltasone (prednisone) drug profile →

More European Organisation for Research and Treatment of Cancer - EORTC trials in Poland

Follow-up in Gynecological Cancer Survivors Active, not recruiting
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence Active, not recruiting
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting
Male Breast Cancer: Understanding the Biology for Improved Patient Care Active, not recruiting
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) Recruiting

Other trials for the same condition

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Active, not recruiting
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Recruiting
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00002462 on ClinicalTrials.gov ↗ ← All trials in Poland